Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival. However, whilst bortezomib elicits initial responses in many myeloma patients, this haematological malignancy remains incurable due to the development o...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Elsevier
2022
|
| Subjects: | |
| Online Access: | https://doaj.org/article/f5e0bdd9d3004cfdbf70bbe296a47fe3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|